aregalu 14 mg filmom obložene tablete
krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - teriflunomid - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 14 mg teriflunomida
tergio 14 mg filmom obložene tablete
viatris limited, damastown industrial park, mulhuddart, dublin, irska - teriflunomid - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 14 mg teriflunomida
tifay 14 mg filmom obložene tablete
stada d.o.o., hercegovačka 14, zagreb, hrvatska - teriflunomid - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 14 mg teriflunomida
teriflunomid pharmas 14 mg filmom obložene tablete
pharmas d.o.o., radnička cesta 47, zagreb, hrvatska - teriflunomid - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 14 mg teriflunomida
teriflunomid pharmascience 14 mg filmom obložene tablete
pharmascience international limited, lampousas, 1, nicosia, cipar - teriflunomid - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 14 mg teriflunomida
teriflunomid zentiva 14 mg filmom obložene tablete
zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - teriflunomid - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 14 mg teriflunomida
teruma 14 mg filmom obložene tablete
pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb, hrvatska - teriflunomid - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 14 mg teriflunomida
tysabri
biogen netherlands b.v. - natalizumab - multipla skleroza - selektivni imunosupresivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
mayzent 0,25 mg/1 tableta filmom obložena tableta
novartis ba d.o.o. - siponimod - filmom obložena tableta - 0,25 mg/1 tableta - jedna filmom obložena tableta sadrži: 0,25 mg siponimoda u obliku siponimod fumaratne kiseline